Brief: Ifinatamab Deruxtecan Biologics License Application For Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
25/09/2026 22:45
BRIEF-Ifinatamab Deruxtecan Biologics License Application For Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn Sept 26 (Reuters) - Merck & Co Inc MRK.N:
IFINATAMAB DERUXTECAN BIOLOGICS LICENSE APPLICATION FOR CERTAIN PATIENTS WITH PREVIOUSLY TREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER VOLUNTARILY WITHDRAWN
MERCK & CO - WITHDRAWAL BASED ON FDA DISCUSSIONS; PHASE 2 DATA DO NOT SATISFY APPROVAL REQUIREMENTS
MERCK & CO - PATIENT ENROLLMENT CONTINUES IN IDEATE-LUNG02 PHASE 3 TRIAL FOR IFINATAMAB DERUXTECAN
MERCK & CO - TWO ADDITIONAL PHASE 3 TRIALS UNDERWAY FOR IFINATAMAB DERUXTECAN IN CRPC AND ESCC
MERCK & CO - DAIICHI SANKYO AND MERCK WITHDRAW BLA FOR IFINATAMAB DERUXTECAN IN ES-SCLC IN U.S.
Source text: ID:nBw2fFVpKa
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))